Curative by Design™
The Verik HCP™ target cancer germline antigen (CGA) AKAP4 in cancer:
Saini S. et al. (2013) A Novel Cancer Testis Antigen, A-Kinase Anchor Protein 4 (AKAP4) Is a Potential Biomarker for Breast Cancer. PLoS ONE 8(2):e57095.
Agarwal S, et al. (2013) The Novel Cancer-Testis Antigen A-Kinase Anchor Protein 4 (AKAP4) Is A Potential Target for Immunotherapy of Ovarian Serous Carcinoma. OncoImmunology 2(5):e24270.
Agarwal S, et al. (2013) Expression and Humoral Response of A-Kinase Anchoring Protein 4 in Cervical Cancer. Int J Gynecol Cancer 23:650.
Gumireddy K. et al. (2015) AKAP4 is a circulating biomarker for non-small cell lung cancer. Oncotarget 6:1.
Li H.-M. et al. (2015) Expression and Clinical Significance of A-Kinase Anchor Protein 4 In Lung Adenocarcinoma Tissue. Thoracic Cancer 7:271.
Jagadish N. et al. (2016) A Novel Cancer Testis Antigen Target A-Kinase Anchor Protein (AKAP4) for the Early Diagnosis and Immunotherapy of Colon Cancer. OncoImmunology 5(2); e1078965.
Li S, et al. (2016) AKAP4 Mediated Tumor Malignancy in Esophageal Cancer. Am J Transl Res 8:597.
Kumar V, et al. (2017) Role Of A-Kinase Anchor Protein (AKAP4) in Growth and Survival of Ovarian Cancer Cells. Oncotarget 8:53124.
LUZP4 (HOM-TES-85; CT-8), a CGA and emerging Verik HCP™ cancer target:
Tureci O, et al. (2002) A Novel Tumor Associated Leucine Zipper Protein Targeting to Sites of Gene Transcription and Splicing. Oncogene 21:3879.
Mischo A, et al. (2006) Prospective Study on the Expression of Cancer Testis Genes and Antibody in 100 Consecutive Patients With Primary Breast Cancer. Int J Cancer 118:696.
LUZP4 is found in 47% of the patients.
Viphakone N, et al. (2015) LUZP4 Defines a New mRNA Export Pathway in Cancer Cells. Nuclei Acids Research doi: 10.1093/nar/gkv070
de Anda-Jauregui G, et al. (2016) Transcriptional Network Architecture of Breast Cancer Molecular Subtypes. Front Physiol 7:568.
Using a network-based approach, the authors identify LUZP4 as a high degree gene in Luminal A, Luminal B and Basal types of breast cancer.
LY6K, a CGA and Verik auxiliary target in cancer:
Kong H. et al. (2012) The Regulatory Mechanism of the LY6K Gene Expression in Human Breast Cancer Cells. J Biol Chem 287:38889.
Kong HK, et al. (2016) Epigenetic Activation of LY6K Predicts the Presence of Metastasis and Poor Prognosis in Breast Carcinoma. Oncotarget 7:55677.
Ishikawa N, et al. (2007) Cancer-Testis Antigen Lymphocyte Antigen 6 Complex Locus K is a Serologic Biomarker and Therapeutic Target for Lung and Esophageal Carcinomas. Cancer Res 67:11601.
Yang W, et al. (2019) Immunogenic Neoantigens Derived From Gene Fusions Stimulate T Cell Responses. Nature Medicine 25:767.
The Verik HCP™target family NUT (NUTM1) fusions in cancer:
French C., (2014) NUT Midline Carcinoma. Nat Rev Cancer 14:149.
Dickson BC, et al. (2018) NTUM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors. Am J Sug Pathol 42:636.
Stathis A, et al. (2016) Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628 Cancer Discovery 6:1.
Sholl LM, et al. (2015) Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterization. J Thorac Oncol 10:951.
Alekseyenko AA, et al. (2016) The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Genes and Development 29:507.
Chau NG, et al. (2016) Intensive Treatment and Survival Outcomes in NUT midline Carcinoma of the Head and Neck. Cancer 122:3632.
Diolaiti D, et al. (2018) A Recurrent Novel MGA-NUTM1 Fusion Identifies a New Subtype of High-Grade Spindle Cell Sarcoma. Cold Spring Harb Mol Case Stud 4:a003194.
Tamura R, et al. (2018) Novel MXD4-NUTM1 Fusion Transcript Identified in Primary Ovarian Undifferentiated Small Round Cell Sarcoma. Genes Chromosomes Cancer 57:557.
Stevens TM, et al. (2019) NUTM1-Rearranged Neoplasia: A Multi-institution Experience Yields Novel Fusion Partners and Expands the Histologic Spectrum. Modern Pathology 32:764.
Presently, Verik HCP targets include shared, T cell-targetable neoantigens in other gene fusions as well.